November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...

Struggles with obesity are a longstanding issue for millions of Americans and thousands of Iowans, but recent advancements in ...

A panelist discusses how glucagon-like peptide-1 receptor (GLP-1) agonists' cardioprotective effects likely stem from multiple physiological mechanisms, including reduced inflammation, improved ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...

People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their ...

Why digital measurements startup Koneksa Health thinks it can help pharma measure if their drugs are effective in people with ...

Mahmoud Nassar, MD, PhD, a trainee in the endocrinology, diabetes and metabolism fellowship program at the Jacobs School of Medicine and Biomedical Sciences, received several prestigious outstanding ...

A t the SupplySide West trade show held earlier this fall, products that provide dietary support for those using GLP-1 ...